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Adult T cell Leukemia/Lymphoma (ATLL) is a mature T cell malignancy associated
with Human T cell Leukemia Virus type 1 (HTLV-1) infection. Among its four main
clinical subtypes, the prognosis of acute and lymphoma variants remains poor. The
long latency (3–6 decades) and low incidence (3–5%) of ATLL imply the involvement
of viral and host factors in full-blown malignancy. Despite multiple preclinical and
clinical studies, the contribution of the stromal microenvironment in ATLL development
is not yet completely unraveled. The aims of this study were to investigate the
role of the host microenvironment, and specifically fibroblasts, in ATLL pathogenesis
and to propose a murine model for the lymphoma subtype. Here we present
evidence that the oncogenic capacity of HTLV-1-immortalized C91/PL cells is enhanced
when they are xenotransplanted together with human foreskin fibroblasts (HFF) in
immunocompromised BALB/c Rag2−/−γc−/− mice. Moreover, cell lines derived from
a developed lymphoma and their subsequent in vivo passages acquired the stable
property to induce aggressive T cell lymphomas. In particular, one of these cell lines,
C91/III cells, consistently induced aggressive lymphomas also in NOD/SCID/IL2Rγc KO
(NSG) mice. To dissect the mechanisms linked to this enhanced tumorigenic ability,
we quantified 45 soluble factors released by these cell lines and found that 21 of
them, mainly pro-inflammatory cytokines and chemokines, were significantly increased
in C91/III cells compared to the parental C91/PL cells. Moreover, many of the increased
factors were also released by human fibroblasts and belonged to the known secretory
pattern of ATLL cells. C91/PL cells co-cultured with HFF showed features reminiscent
of those observed in C91/III cells, including a similar secretory pattern and a more
aggressive behavior in vivo. On the whole, our data provide evidence that fibroblasts,
one of the major stromal components, might enhance tumorigenesis of HTLV-1-infected
and immortalized T cells, thus throwing light on the role of microenvironment contribution
in ATLL pathogenesis. We also propose that the lymphoma induced in NSG mice by
injection with C91/III cells represents a new murine preclinical ATLL model that could be
adopted to test novel therapeutic interventions for the aggressive lymphoma subtype.
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INTRODUCTION
According to the criteria of the World Health Organization
[WHO] (2008) for classification of tumors originating
from hematopoietic and lymphoid tissues, Adult T cell
Leukemia/Lymphoma (ATLL) is defined as a peripheral T cell
neoplasia linked to infection with Human T cell Leukemia
Virus type 1 (HTLV-1), a virus identified first by Gallo and
co-workers in 1980 (Poiesz et al., 1980). ATLL incidence is
therefore linked to the prevalence of HTLV-1 infection, which
is not uniformly distributed around the world; clusters of
high HTLV-1 prevalence are mainly found in Southwestern
Japan, the Caribbean Basin and some parts of Africa and
South America (Gessain and Cassar, 2012). ATLL develops
almost exclusively in adults, although a few cases in children
have been reported (de Oliveira et al., 1990; Watanabe, 2017).
The diagnosis is mainly based on clinical features, presence
of HTLV-1 infection and, when detected, peculiar tumor cell
morphology, represented by atypical circulating lymphocytes
with petal-shaped nuclei (Matutes, 2007). From the clinical
point of view, ATLL is characterized by a high heterogeneity
in its presentation and clinical course. Four main subtypes
have been described (Shimoyama, 1991), two aggressive and
fast-growing (acute leukemia, lymphoma) and two indolent
(smoldering, chronic) variants. A new classification has recently
been proposed that combines clinical features with specific
genetic aberrations shown to have a prognostic value (Kataoka
et al., 2018). Treatment strategies are based on ATLL subtype,
and antiviral therapy is usually effective in slowly progressing
subtypes. Prognosis of fast-growing variants remains poor in
spite of various attempts of pharmacologic treatments (Hermine,
2015; Katsuya et al., 2015).
The very prolonged latent period (decades) between primary
infection and development of full-blown disease and the relative
rare occurrence of ATLL among asymptomatic HTLV-1 carriers
(3–5%) suggest that additional genetic and/or epigenetic changes
in infected T cells as well as host factors are necessary for ATLL
induction. Besides ATLL, HTLV-1-infected subjects may also
feature opportunistic infections (Nakada et al., 1987) and develop
chronic inflammatory disease such as myelopathy (Gessain et al.,
1985; Osame and Igata, 1989), arthropathy, myositis, uveitis,
and dermatitis (Yamano and Sato, 2012). Thus, circumstantial
evidence indicates that the infection with HTLV-1 induces
deficiency and dysregulation of host immunity.
HTLV-1 belongs to the deltaretrovirus genus, together with
the simian T lymphotropic virus and bovine leukemia virus.
HTLV-1 is a complex retrovirus whose genome comprises
structural, regulatory and accessory genes. Accumulating
evidence indicates that the regulatory gene tax is crucially
involved in ATLL pathogenesis. In fact, Tax protein exhibits
pleiotropic functions (Romanelli et al., 2013); besides
transcriptionally activating its long terminal repeats (Felber et al.,
1985; Seiki et al., 1986), it interacts with cellular transcription
factors (NF-kB, CREB, and AP-1) and upregulates the expression
of multiple cellular genes involved in cell proliferation and
genomic instability (Armstrong et al., 1993; Baranger et al., 1995;
Munoz and Israel, 1995; Fujii et al., 2000; Grassmann et al., 2005;
Fochi et al., 2018). However, in the majority of cases, ATLL cells
show a Tax-low or Tax-negative phenotype, suggesting that Tax,
while critical for T cell immortalization and transformation,
may be not crucial in late stages of ATLL (Takeda et al., 2004).
In contrast, another viral gene, the HTLV-1 basic leucine zipper
factor (HBZ) encoded in the minus strand of the viral genome,
appears to be transcribed in all cases of ATLL (Gaudray et al.,
2002). Furthermore, it has been reported that HBZ mRNA, but
not HBZ protein, could induce T cell proliferation and promote
cell survival (Satou et al., 2006). Thus, a current hypothesis is
that transactivation by Tax is needed to initiate the processes
that lead to ATLL, while HBZ is responsible for maintaining the
neoplastic phenotype of ATLL cells (Matsuoka and Jeang, 2007;
Giam and Semmes, 2016).
Bidirectional communication of potentially oncogenic cells
with surrounding stroma creates a tissue microenvironment
permissive to disease initiation and progression. Among the
stromal components, fibroblasts play a prominent role; the
tumor-promoting activity of cancer-associated fibroblasts has
been extensively studied in epithelial cancers (Olumi et al., 1999;
Erez et al., 2010). Within the tumor stroma, fibroblasts, likely
through a transforming growth factor beta signaling, acquire
an activated phenotype which is mainly characterized by their
expression of alpha-smooth muscle actin similar to that observed
in the wound healing process (Vaughan et al., 2000). These cells
are provided with an armamentarium of released factors that
can alter tissue homeostasis, promote angiogenesis, cancer cell
proliferation and invasiveness, and recruit immunosuppressive
and tumor-promoting cells (Kalluri and Zeisberg, 2006; Mueller
et al., 2007; Erez et al., 2010; Bissell and Hines, 2011). Specific
bone marrow stromal niches have been identified for leukemia
development (Jin et al., 2008; Zhang et al., 2012). Concerning
ATLL, in vitro interaction with epithelial and fibroblastic cell lines
was shown to induce apoptosis resistance in primary ATLL cells
and ATLL cell lines (Miyatake et al., 2013, 2015) as well as viral
latency (Kinpara et al., 2009), highlighting the role of stromal
components in ATLL pathogenesis.
Different preclinical models have been developed to better
understand the pathogenesis of ATLL and HTLV-linked
degenerative/inflammatory diseases (Panfil et al., 2013). Good
models for HTLV-1 infection have been established in non-
human primates, rabbits and rats (Dodon et al., 2012; Hajj et al.,
2012). However, mice are preferred as they are more manageable
and cost-effective models to study the virus/host factors critical
for ATLL induction and for evaluation of its specific treatments.
Xenografts of ATLL cells or some ATLL-derived cell lines in
immunocompromised mice successfully replicated features
of ATLL (Parrula et al., 2009). On the other hand, T cells
immortalized in vitro by HTLV-1 showed no or poor growth,
depending mainly on the host constitutive immunodeficiency
degree, the innate immunity by natural killer (NK) cell antitumor
activity being particularly critical for restraining the engraftment
(Ishihara et al., 1992; Feuer et al., 1993, 1995; Imada et al., 1995;
Liu et al., 2002).
The aim of the present study was to analyze the evolution
of HTLV-1-infected T lymphocytes from the immortalized
status, commonly observed in asymptomatic carriers, to the
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quite rare neoplastic transformation leading to clinically
overt ATLL. Among the multiple factors involved in this
oncogenic switch, including genetic and epigenetic cell
alterations, our attention was focused on the influence of
one of the major microenvironment components, specifically
fibroblasts. Moreover, we established of a highly lymphomagenic
C91/PL-derived cell line that, when xenotransplanted into
immunodeficient NSG mice, may constitute a new preclinical
mouse model for the lymphoma variant of ATLL.
MATERIALS AND METHODS
Cell Lines
The HTLV-1-immortalized C91/PL cell line was established by
co-cultivation of umbilical cord blood T cells with leukemic T
cells from an ATLL patient (PL) (Popovic et al., 1983), and
was originally obtained from Prof. Robin Weiss (Chester Beatty
Laboratories, London). This cell line and its ex vivo-derived
cell lines (designated as C91/I, C91/II and C91/III) were
grown in RPMI 1640 (Sigma-Aldrich, Munich, Germany)
supplemented with 10% fetal calf serum (FCS, Gibco, Foster
City, CA, United States), 2 mM L-glutamine (Gibco) and
50 µg/mL gentamycin (Sigma-Aldrich) (complete medium).
Human foreskin fibroblasts (HFF) were a kind gift from Dr.
Abatangelo and Dr. Zavan (University of Padova). HFF were
propagated in Dulbecco’s modified Eagle Culture Medium
(DMEM, Sigma-Aldrich) supplemented with 10% FCS, 2 mM
L-glutamine and 50 µg/mL gentamycin.
Analysis of the clonal T cell receptor (TCR) beta chain
and gamma chain gene rearrangements in C91/PL cells
and in C91/PL-derived cells was carried out using the
IdentiCloneTM TCRB + TCRG T cell Clonality Assay
(Invivoscribe Technologies, San Diego, CA, United States),
according to the manufacturer’s instructions. Short tandem
repeat (STR) profile of C91/PL and C91/PL-derived cell lines was
carried out with the PowerPlex 18D System (Promega, Madison,
WI, United States) using an Applied Biosystems 3130XL
genetic analyzer and Genemapper ID Ver. 3.2.1 software (BMR
Genomics S.r.l., Padua, Italy). As an STR profile of C91/PL cells is
not available in DMSZ, ATCC, and COG databases, C91/PL cells
and their more tumorigenic counterparts (C91/II and C91/III)
were authenticated by comparing the STR profile obtained
with 18 genetic markers to that determined using the C91/PL
cells received by the National Institute for Biological Standards
and Controls (NIBSC), United Kingdom. The presence of the
HTLV-1 provirus was confirmed in all ex vivo cell lines by
qualitative single-round PCR with primer pairs specific for the
tax region as previously reported (Calabro et al., 1993). All cell
lines were mycoplasma-free, as confirmed by periodical PCR
check.
Mice
BALB/c Rag2/Common γ chain (γc)–double KO
(Rag2−/−γc−/−) mice were originally received from the
Freiburg University Medical Center, Germany. Null mutation
of the RAG2 gene prevents B and T lymphocyte development
in these mice, while absence of the cytokine receptor common
gamma chain, required for signal transduction of multiple
cytokines [including interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15,
and IL-21] prevents NK cell maturation. Mice were inbreed and
maintained in our animal facility, and were used in the first set of
experiments and for the in vivo passages of the C91/PL-derived
cells. Because of a temporary closure of our animal SPF facility for
enlargement and renovation, all mouse colonies were eliminated
and subsequently, after a 7 month-gap, restored with new stocks.
Therefore, the second set of experiments was conducted with
BALB/c Rag2−/−γc−/− (BRG) mice (“excluded flora,” i.e., free of
rodent pathogens and seven selected opportunistic pathogens as
well as Segmented Filamentous Bacteria) obtained from Taconic
(Germantown, NY). Other experiments were performed using
NOD/SCID/IL2Rγc KO (NSG) mice, obtained from Charles
River (Charles River Laboratories, Calco, Italy), that combine
the NOD/SCID background to the lack of a functional common
gamma chain.
Ethics Statement
This study was carried out in accordance with the institutional
guidelines that comply with the Italian Animal Welfare Law
(D.L. No. 116/1992; and subsequent documents). The project
was evaluated and approved by the local ethics committee of
the University of Padova (Comitato Etico di Ateneo per la
Sperimentazione Animale, CEASA) and communicated to the
relevant Italian authority (Italian Ministry of Health, VI Office)
(Project No. 32/2009; Permit Protocol No. 51740, 15/09/2010).
The project had to be renewed, and it was evaluated and approved
by the Italian Ministry of Health (Project and Permit protocol No.
932/2016, 10/10/2016).
Assessment of the Contribution of
Fibroblasts to Lymphoma Growth in Vivo
Exponentially growing HFF and C91/PL cells mixed in a 1:2
ratio were suspended in a final density of 6 × 107 total cells/mL,
and 0.1 mL of this cell suspension (i.e., 2 × 106 HFF and
4 × 106 C91/PL) was injected intraperitoneally (i.p.) into each
mouse. Control mice were i.p. injected with 4 × 106 C91/PL
cells. Mice were checked biweekly for cachexia and presence of
abdominal masses. For ethical reasons, tumor-bearing animals
were killed when presenting signs of suffering, and each mouse
was considered to have died from tumor progression on this date.
At necroscopy, the finding of organ involvement, abdominal and
pelvic tumor masses were considered lymphoma growth, which
was subsequently confirmed by histological examination.
Assessment of Engraftment and
Tumorigenesis of C91/PL-Derived Cell
Lines
Fragments of masses from Rag2−/−γc−/− mice affected by
lymphomatous growth were processed under sterile conditions
and the obtained cell suspension was used to set up ex vivo
cultures. After in vitro growth for 3–4 weeks, these cells were
used as inoculum to assess their ability to induce a lymphomatous
growth in mice. Different cell lines were thus obtained from
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the subsequent in vivo passages: C91/I, C91/II and C91/III,
corresponding to the first, second and third in vivo passage,
respectively. Each cell line was then tested for lymphoma
induction in different doses and ages of injected mice.
Engraftment efficiency and tumorigenesis of C91/III cells were
also assessed in NSG mice. Six-day-old mice were i.p. injected
with 4 × 106 C91/III cells/mouse. Four-week-old mice were
injected with 1 × 106 and 4 × 106 C91/III cells/mice (five mice
per group). Moreover, we further analyzed the contribution of
HFF to lymphoma growth by injecting C91/PL cells after in vitro
co-culture with HFF. To this end, 5-day-old NSG mice were
injected i.p. with 4 × 106 co-cultured C91/PL cells (nine mice).
Control mice were injected i.p. with 4 × 106 C91/PL cells (seven
mice). Mice were checked, culled and analyzed as reported above.
Histology and Immunohistochemistry
Fragments of infiltrated murine organs and tissues were fixed
in 10% formalin and embedded in paraffin. Sections were
cut (4-mm thick) from ex vivo samples and prepared for
appropriate staining. Hematoxylin–eosin staining was used for
histological diagnosis. Sections were immunostained for CD25
(Leica Biosystems, Nussloch, Germany) and for Ki67 (Dako,
Glostrup, Denmark), as previously reported (Di Stefano et al.,
2008).
Immunophenotypic and Viral
Characterization of C91/PL, C91/III and
HFF-Co-cultured C91/PL Cell Lines
C91/PL, C91/III and HFF-co-cultured C91/PL were analyzed
for the expression of surface antigens by flow cytometry.
The following anti-human monoclonal antibodies were used:
fluorescein isothiocyanate (FITC)-conjugated anti-CD1a (BD
Pharmingen, Franklin Lakes, NJ, United States), phycoerythrin
(PE)-conjugated anti-CD2 (Life Technologies, Carlsbad, CA,
United States), Alexa488-conjugated anti-CD3, anti-CD4,
and anti-CD25 (Bio-Rad Laboratories, Inc., Hercules, CA,
United States), phycoerythrin-Cy5 (PC5)-conjugated anti-CD5
and anti CD-7 (Coulter, Fullerton, CA, United States), FITC-
conjugated anti-CD34 (BD Pharmingen), PE-conjugated
anti-CD117 (Miltenyi Biotec, Bergisch Gladbach, Germany),
Allophycocyanin (APC)-conjugated anti-CD133 (Miltenyi
Biotec), A488-conjugated anti-FOXP3 (AbD Serotec, Oxford,
United Kingdom), PE-conjugated anti-CD54 (eBioscience,
Inc., San Diego, CA, United States), and FITC-conjugated
anti-cell adhesion molecule 1 (CADM1, Medical and Biological
Laboratories, Nagoya, Japan). Samples were analyzed on a
BD LSR II flow cytometer (BD Biosciences, Milano, Italy).
All cytofluorimetric data were analyzed using Kaluza Analysis
software Ver. 1.3 (Beckman Coulter, Brea, CA, United States).
Quantitative analysis of HTLV-1 transcripts in C91/PL,
C91/III and HFF-co-cultured C91/PL cells was performed as
previously described (Rende et al., 2011; Cavallari et al., 2013).
Quantitative Analyses of Soluble Factors
To measure soluble factors released by C91/PL, C91/III
and HFF-co-cultured C91/PL cells, cells were seeded at a
concentration of 1 × 106/mL. Supernatants were collected
after 72 h and centrifuged for 5 min at 200 g. Cell pellets
were discarded, and supernatants were centrifuged for 30 min
at 2,800 g to eliminate cell debris. Supernatants were also
collected from the three cell lines kept in culture to evaluate
concentration fluctuations and consistency of detectable factors
during standard passage. The secretory pattern of HFF was
measured by seeding 3× 105 cells in a six-well plate; supernatants
were collected after 72 h and processed as described above.
To compare the profile and amount of factors released by all
cell lines, a Luminex xMAP approach was used (ProcartaPlex
Human Cytokine/Chemokine/Growth Factor Panel 1 96 tests,
Affymetrix eBioscience Ltd., Hatfield, United Kingdom) for
the multianalyte detection of 45 secreted proteins. This assay
detects the following proteins: IL-1 receptor antagonist (IL-1RA),
IL-1alpha (IL-1α), IL-1beta (IL-1β), IL-2, IL-4, IL-5, IL-6, IL-7,
IL-8/ C-X-C motif chemokine ligand 8 (CXCL8), IL-9, IL-10, IL-
12p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-
31, leukemia inhibitory factor (LIF), tumor necrosis factor alpha
(TNFα), TNF beta/lymphotoxin-alpha (TNFβ/LTA), interferon
alpha (IFNα), IFN gamma (IFNγ), growth-regulated oncogene-
alpha GROα/CXCL1, eotaxin/C-C motif chemokine ligand 11
(Eotaxin/CCL11), IFNγ-induced protein 10 (IP10)/CXCL10,
monocyte chemotactic protein-1 (MCP-1)/CCL2, macrophage
inflammatory protein-1 alpha (MIP-1α)/CCL3, MIP-1 beta, MIP-
1β/CCL4, regulated on activation normal T cell expressed and
secreted (RANTES)/CCL5, stromal cell-derived factor 1 alpha
(SDF-1α/CXCL12), brain-derived neurotrophic factor (BDNF),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
hepatocyte growth factor (HGF), placental growth factor (PLGF),
epidermal growth factor (EGF), fibroblast growth factor 2
(FGF-2), platelet-derived growth factor-BB (PDGF-BB), stem
cell factor (SCF), nerve growth factor beta (βNGF), vascular
endothelial growth factor A (VEGF-A), VEGF-D.
IL-8/CXCL8 and TNFα were also quantified using cytokine-
specific assays (Human IL-8-ELISA and Human TNFα-ELISA
Ready-SET-Go Kits, Affymetrix eBioscience Ltd.), according to
the manufacturer’s instructions.
Analysis of the Crosstalk Between
C91/PL Cells and HFF
To assess whether HFF were able to modulate C91/PL cell
turnover, 2 × 105 C91/PL cells were co-cultured in the
presence or absence of semiconfluent HFF seeded onto a
six-well plate. Induced apoptosis was measured after 24, 48, and
72 h of culture by flow cytometry after Annexin V/Propidium
Iodide (PI) staining (Annexin-V-FLUOS Staining Kit, Roche
Diagnostics, Mannheim, Germany). Apoptosis was induced by
serum reduction (5% FCS). Proliferation was analyzed by flow
cytometry after staining with carboxyfluorescein succinimidyl
ester (Cell TraceTM CFSE, Life Technologies).
Long-term HFF-co-culture of C91/PL cells was carried out in
T75 flasks to periodically assess morphological and phenotypic
changes. Two-month co-culture of C91/PL cells was carried out,
and then cells were removed from co-culture and maintained
as long as 6 weeks in culture to ensure the absence of
Frontiers in Microbiology | www.frontiersin.org 4 June 2018 | Volume 9 | Article 1215
fmicb-09-01215 June 11, 2018 Time: 17:14 # 5
Vicario et al. A Preclinical Model for the ATLL Lymphoma Variant
residual fibroblasts. The secretory pattern, the profile of HTLV-1
transcripts and the ability to induce in vivo lymphoma of these
long-term co-cultured cells were analyzed at this time point.
To assess the contribution of soluble factors in the crosstalk
between C91/PL cells and HFF, short-term co-cultures in six-well
plates were set up, with C91/PL cells added directly to the
HFF or placed into transwell chambers (BD Falcon Cell Culture
Inserts, Durham, NC, United States; pore size 0.4 µm). The
amount of secreted IL-8/CXCL8 and TNFα was measured in the
supernatants collected after 3 and 10 days of co-culture.
Statistical Analyses
Curves reporting the percentage of survivors over time were
estimated by the Kaplan–Meier method and compared with the
log-rank test. Data analysis was performed using the MedCalc
statistical software (Mariakerke, Belgium). Statistical data are
presented as mean ± standard deviation. Two-sided Student’s
t-test was used to estimate statistical significance of differences
between the two cell lines. P-values < 0.05 were considered
significant.
RESULTS
Co-inoculation of Fibroblasts Promotes
the Tumorigenesis of C91/PL Cells
Preliminary experiments conducted to xenograft, either i.p.
or subcutaneously, the HTLV-1-immortalized C91/PL cell line
at different doses (from 2 to 10 × 106 cells per mouse)
in immunodeficient adult Rag2−/−γc−/− mice did not lead
to tumor development (data not shown). The evidence that
fibroblasts are effective in promoting tumor initiation and
progression in different mouse models of carcinogenesis (Bissell
and Hines, 2011) prompted us to analyze whether co-injection
of fibroblasts with C91/PL cells in newborn Rag2−/−γc−/−
mice could facilitate the engraftments of this cell line. Thus,
we performed a first set of experiments using six 4–6-day-
old Rag2−/−γc−/− mice per group: control mice were i.p.
injected with 4 × 106 C91/PL cells, whereas the experimental
group received the same dose of C91/PL cells mixed with HFF
in a 2:1 ratio. This experiment was repeated twice and each
experiment was stopped after 200 days. As shown in Table 1,
all control mice (12 of 12) were disease-free throughout the
experiment and autopsy did not disclose any pathological sign.
Conversely, among the 12 animals receiving C91/PL cells mixed
TABLE 1 | Lymphomagenic efficiency of C91/PL cells in Rag2−/−γc−/− mice.
No. of positive mice/total No. of micea
C91/PL 0/12
C91/PL + HFF 4/12b
a4-6-day-old mice were intraperitoneally (i.p.) inoculated with 4 × 106 C91/PL
alone or with 2 × 106 human foreskin fibroblasts (HFF) cells. bMice with
lymphomatous abdominal infiltration were culled at 70, 90, 120, and 195 days
after i.p. cell inoculation.
with HFF, four developed lymphoma with a median survival time
of 105 days.
At necroscopy, tumor masses were found in the abdomen,
often extending into the pelvic cavity. The tumor infiltrated the
mesentery, the small and large intestine, the liver hilum and the
pancreas. The spleen was only slightly enlarged and free from
lymphoma invasion. Histologically, the neoplastic tissue was
composed of large pleomorphic cells with abundant eosinophilic
cytoplasm and vesicular basophilic, irregularly lobulated nucleus
with prominent nucleoli. Numerous multinucleated syncytial
giant cells were also observed and mitotic figures were common.
Necrotic and hemorrhagic areas were sometimes found within
the lymphomatous masses and organ infiltrates.
Thus, in this set of experiments, using mice deriving from an
in-house long-lasting Rag2−/−γc−/− colony, co-inoculation of
fibroblasts was found to trigger the oncogenic potential of the
HTLV-1-immortalized T cell line.
Ex Vivo C91/PL-Derived Cell Lines
Induce Aggressive Lymphoma
The tumor mass from one of the four diseased mice of the
first set of experiments, culled 90 days after cell injection, was
removed and processed under sterile conditions and a continuous
cell culture was obtained (C91/I), as shown in Figure 1A. These
cells were then i.p inoculated into 4–5-day-old Rag2−/−γc−/−
mice at different doses and all (7 of 7) animals belonging
to the group injected with the higher dose developed a very
aggressive and invasive lymphoma with a short latency period
(median survival, 15 days, Table 2). Two subsequent in vivo
passages, followed by establishment of tumorigenic cell lines
(C91/II and C91/III), were performed. C91/II cells engrafted
into mice with high efficiency and also induced aggressive and
diffused tumor masses in 2–4-week-old mice (Table 2). All mice
(10 out of 10) inoculated with 4 × 106 C91/III cells at 4–8 days
of age developed a lymphoma with a median latency of 32 days.
C91/II and C91/III cell lines showed an increased lung tropism,
resulting in frequent lung metastases as well as in lymphomatous
lung involvement as primary presentation. Mice inoculated
with these cell lines showed a pathological picture similar
to that described above and shown in Figure 1B. Moreover,
involvement by lymphomatous whitish tissue was also observed
in the renal pericapsular fatty tissue, with invasion of cortical
kidney parenchyma. In some animals, tumor infiltration was
also found in ovary, uterine wall and testis. The abdominal and
diaphragmatic peritoneal surface was frequently scattered with
small neoplastic white nodules and, in two mice, injected with
4× 106 C91/III cells at 4 days of age, slightly hemorrhagic ascitic
fluid was also found in the peritoneal cavity. Furthermore, the
muscles surrounding the lumbar spinal column often appeared
infiltrated by whitish tumor tissue. Microscopically, mice showed
histological and cytological features indicative of lymphomatous
growth (Figure 1C); kidney, pancreas, liver and intestinal wall
were constantly infiltrated (Figures 1D–G). Neoplastic white
nodules or small metastatic cell embolic aggregates and single
neoplastic cells (Figure 1H) within capillaries were found
in the lung of 10 mice. Immunochemical staining of lung
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FIGURE 1 | Xenotransplantation of C91/PL-derived cell lines in
Rag2−/−γc−/− mice. (A) Schematic representation of the in vivo
experiments. C91/PL cells intraperitoneally co-injected with human fibroblasts
into a 5-day-old Rag2−/−γc−/− mouse lead to lymphoma development.
A fragment of the induced abdominal lymphomatous mass was processed
under sterile conditions and cultured in vitro to establish a C91/PL-derived
lymphomatous cell culture (C91/I). Injection of these cells into a
Rag2−/−γc−/− mouse led to an aggressive Adult T cell Leukemia/Lymphoma
(ATLL)-like lymphoma. Additional in vitro/in vivo passages were done with the
establishment of two other lymphomatous cell lines (C91/II and C91/III).
(B) Macroscopic view of lymphomatous masses developed in a mouse
injected with C91/III cells involving mesenteric nodes (white arrow) and the
liver hilum (green arrow). (C) Hematoxylin and eosin staining of formalin-fixed,
paraffin-embedded tissues shows tumor mass composed of pleomorphic
cells mixed with syncytial cells (white arrow) with giant nuclei; the green arrow
shows a pleomorphic cell with a giant nucleus. Original magnifications 400×.
(D–G) Lymphomatous infiltration of kidney pericapsular area, pancreas, liver,
and intestinal wall, respectively. Original magnification 200×. (H) Lung
parenchyma with small embolic metastasis; arrow indicates abnormal tripolar
mitosis. Original magnification 400×.
TABLE 2 | Lymphoma induction by C91/PL-derived cells in Rag2−/−γc−/− mice.
C91/PL-
derived
cells
Age of mice
(days)
No. of cells
injected
No. of positive
mice/total No.
of mice
Median
latency
(Range, days)
C91/I 4–5 1 × 106 0/4 –
4–5 4 × 106 7/7 15 (12–34)
C91/II 4–8 4 × 106 15/15 17 (9–41)
16 4 × 105 3/3 112 (61–112)
30 4 × 105 3/7 133 (53–202)
30 4 × 106 3/6 34 (26–34)
C91/III 5 1 × 106 2/3 52 (41–62)
4–8 4 × 106 10/10 32 (17–62)
metastases to detect human CD25 (i.e., IL-2 receptor alpha
chain) showed the presence of a consistent number of neoplastic
cells (Supplementary Figure S1). The spleen was free from
lymphomatous involvement, being characterized by erythroid
and myeloid hyperplasia of the red pulp.
These findings indicated that the highly tumorigenic capacity
acquired by C91/PL cells following co-transplantation with HFF,
and through in vitro/in vivo passages, is a stable and reproducible
property.
In Vivo Validation of the Supporting Role
of Fibroblasts
To further confirm the supporting activity exerted by fibroblasts,
a second set of experiments was performed. As the previously
tested Rag2−/−γc−/− mice were no longer available in our
animal house (see section “Materials and Methods”), we used
brand new mice with identical knock-out genes (BALB/c
Rag2−/−γc−/−, BRG), but obtained from a different source and
with a well-defined, restricted microbiota, that were endowed
with high susceptibility to tumor xenoengraftment (Yamamoto
and Schiestl, 2014; Rosshart et al., 2017). The experimental setting
was identical to the previous one and two groups of six, 5-day-
old, BRG mice were similarly i.p. injected with C91/PL cells
alone (control group) or mixed with HFF in a 2:1 ratio. Mice
injected with HFF and C91/PL cells developed lymphoma as
did control mice injected with C91/PL cells alone (Figure 2A).
However, HFF co-inoculation significantly triggered lymphoma
development compared to control mice, with a twofold decrease
in survival time (log-rank test, p = 0.0168). The pathological
findings of mice developing lymphoma were substantially similar
to those observed in the first set of experiments.
Therefore, these data indicate that, in appropriate
hosts, C91/PL cells may per se induce lymphoma in
immunocompromised mice. However, HFF co-inoculation
exerts a significant enhancement of the oncogenic potential
of C91/PL cells in vivo, confirming the relevance of stromal
contribution in HTLV-1-mediated lymphomagenesis.
C91/III Cells Efficiently Engraft in NSG
Mice
To further confirm the constitutive capability of C91/III cells to
induce lymphoma with high reproducible efficiency, a different
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FIGURE 2 | Kaplan–Meier survival curves for mice injected with C91/PL cells,
C91/PL cells with human foreskin fibroblasts (HFF), or C91/III cells.
(A) Five-day-old BRG mice intraperitoneally injected with C91/PL cells and
HFF showed a statistically significant decrease in the survival time compared
to control mice injected with C91/PL cells (six mice per group).
(B) Engraftment of C91/III cells in NSG mice. Survival curves for 6-day-old or
4-week-old mice intraperitoneally inoculated with different doses of C91/III
cells (five mice per group). P-values reported in the figure were calculated by
the log-rank test; p-value in B refers to all pairwise comparisons and was
adjusted for multiple comparisons with Bonferroni correction.
mouse strain was employed. Therefore, mice of NSG strain
were i.p. injected with C91/III cells. Figure 2B shows the
Kaplan–Meier survival curves for mice injected with C91/III cells
at 6 days or 4 weeks of age (five mice each group). Six-day-old
mice injected with 4 × 106 cells had a median survival time
(33 days) similar to that of baby Rag2−/−γc−/−, and showed
at necroscopy diffused mesenteric lymphomatous masses; two of
them showed macroscopic lung metastatic nodules. Interestingly,
the same dose of C91/III cells induced lymphoma in all young
adult mice with a median survival time of 47 days. Moreover, even
at a dose of 1× 106 cells, all young adult mice died from a diffused
tumor, with a median survival time of 78 days. At necroscopy,
diseased mice showed abdominal tumor masses involving the
peritoneal and pelvic organs and frequent lung involvement.
These data show that C91/III cells, even in low dose,
engraft with high efficiency in NSG mice and induce an
aggressive lymphoma with a relative short latency in young
adult mice. Therefore, C91/III cells xenotransplanted in the adult
NSG mouse setting might usefully be employed for preclinical
evaluation of drug candidates for ATLL lymphoma variant.
Characterization of the Tumorigenic
C91/III Cell Line
Based on the results obtained in NSG mice, C91/III cells were
chosen as a representative tumorigenic cell line for further
characterization. Analysis of clonality showed an identical
monoclonal pattern in the rearrangement of the β and γ chains
of the TCR gene in C91/PL and C91/III cells (not shown). STR
profile of C91/III cells further confirmed derivation from the
parental cell line (Supplementary Table S1). The presence of the
HTLV-1 provirus was confirmed by a qualitative standard PCR
using primer pairs specific for the tax region (not shown).
C91/III cells morphologically resembled C91/PL cells,
although the percentage of giant cells was higher (Figure 3A).
Phenotypic analyses did not disclose substantial differential
expression of surface markers (Table 3). C91/III cells were
all CD4+/CD25+ as the parental C91/PL cell line, they
expressed similar levels of CD5 and, at high intensity, the two
adhesion molecules CADM1 and CD54. C91/PL and C91/III
cells did not stain for stem cell markers (CD34, CD117, and
CD133). Intracellular staining for forkhead box P3 (FOXP3)
transcriptional factor was similar in the two cell lines.
Comparative qRT-PCR analysis of the viral transcript profile
in C91/PL and C91/III cells showed no significant variation in
the expression of the gag, env, and tax/rex mRNAs. In contrast,
all the transcripts coding for the accessory proteins showed a
marked increase in C91/III cells, ranging from 4-fold (p21rex)
to 18-fold (p13). Statistical analysis showed that these differences
were significant (p ≤ 0.05) except for HBZ Sp1 (p = 0.056)
(Figure 3B).
Characterization of the Secretory Profile
of C91/PL, C91/III Cells, and HFF
To assess whether C91/III cells were characterized by a
differential profile of secreted soluble factors, we measured 45
cytokines, chemokines and growth factors in the supernatants of
both cell lines (Supplementary Table S2). The secretory profile of
C91/III cells did not qualitatively differ from that of the parental
cell line, at least in the 45 soluble factors tested using the Luminex
technology. However, the release of 22 factors was quantitatively
altered in C91/III cells, as shown in Figure 4A. The amount of 21
soluble factors was significantly increased in C91/III cells, while
only one (IP-10/CXCL10) was reduced. Many of the upregulated
factors were direct pro-inflammatory cytokines (IL-1α, IL-6,
TNFα) and α and β chemokines (Supplementary Table S2), able
to amplify the inflammatory response. Interestingly, the highest
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FIGURE 3 | Morphologic and viral characterization of C91/PL and C91/III cell lines. (A) Phase contrast images of C91/PL and C91/III cells in standard culture
conditions. The tumorigenic C91/III cell line showed a higher percentage of multinucleated giant cells. Original magnification 100×; Upper right-end side insert 200×.
(B) Profile of Human T cell Leukemia Virus type 1 (HTLV-1) transcripts. C91/III cells showed a statistically significant increase in the normalized copy number (NCN) of
all transcripts encoding the viral accessory proteins compared to C91/PL cells. NCN values were calculated by normalizing the absolute copy number of each
transcript for the copy number of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcripts. Values are the mean of three independent measurements
performed in triplicate; standard error bars are shown. ∗p < 0.05, ∗∗p < 0.01.
increase was shown by IL-8/CXCL8, a chemokine involved
in tumorigenesis through autocrine and paracrine signaling
responsible for the triggering of invasiveness, angiogenesis and
metastasis (Balkwill and Mantovani, 2001).
We also characterized the secretory pattern of HFF used
in our in vivo experiments (Supplementary Table S2). The
high release of many chemokines and IL-6 indicated that HFF
partially overlapped the secretory profile of “activated” fibroblasts
(Kalluri and Zeisberg, 2006). Among the growth factors, HGF,
βNGF, and VEGF-A were found in measurable amounts, while
EGF, FGF-2, and PDGF-BB, which are other soluble mediators
secreted by activated fibroblasts, were not detected. Interestingly,
some of the factors released by C91/III cells showing the most
pronounced increase were characteristic of the HFF secretory
profile (Figure 4B) suggesting that C91/III cells might have
reinforced autonomous stimulatory activity, thus becoming
independent from the microenvironment support.
Analysis of the Crosstalk Between
C91/PL Cells and HFF
As HFF were found to trigger tumorigenesis of C91/PL cells,
we studied the impact of HFF on C91/PL cells in a co-
culture system. Results showed that co-cultivation with HFF
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TABLE 3 | Immunophenotypic characterization of C91/PL and C91/III cells.
Marker C91/PL C91/III
CD1a –a –
CD2 – –
CD3 – –
CD4 ++++b +++/++++
CD5 ++/+++ ++/+++
CD7 – –
CD25 +++ ++/+++
CD34 – –
CD117 – –
CD133 – –
CD54 ++++ ++++
CADM1 ++++ ++++
FOXP3 +++ +++
aNegative. b+ indicates that <25% of cells expressed the analyzed surface marker
by cytofluorimetric analyses; ++ indicates 25–50%; +++ indicates 50–75%;
++++ indicates >75%.
significantly decreased the induced apoptosis in C91/PL cells
after 48 and 72 h of co-culture (Figures 5A,B). On the other
hand, HFF-co-cultured C91/PL cells showed proliferation rates
comparable to those of C91/PL cells, as assessed by CFSE labeling
(Figure 5C). Of interest, short-term and long-term co-culture
with HFF led to morphologic changes in C91/PL cells resembling
those of C91/III cells (Figure 5D, see Figure 3A for comparison),
whereas immunophenotypic variations were not observed for the
periodically checked surface antigens (CD4, CD25, and CD54,
data not shown).
In vivo lymphomagenic activity was analyzed in 5-day-old
NSG mice injected i.p. with co-cultured C91/PL cells, which
showed a statistically significant reduction (log-rank test,
p = 0.0005) in the survival compared to control mice i.p. injected
with C91/PL cells (Figure 5E).
On the other hand, no significant variation in the expression of
any of the viral mRNAs was detected (Figure 5F), suggesting that
the co-culture microenvironment does not have an impact on
either HTLV-1 rate of transcription or on the alternative splicing
pattern of viral mRNAs.
Interestingly, the secretory pattern of co-cultured C91/PL
cells was similar, albeit not identical, to that found in C91/III
cells (Supplementary Figure S2), with a statistically significant
increase in IL-8/CXCL8 and many other chemokines. Among
pro-inflammatory factors, a significant increase was evidenced
for TNFα, whereas IL-1α and IL-6 were augmented but not at
a statistically significant level.
To assess the relevance of the paracrine crosstalk between
C91/PL cells and HFF, two soluble factors were measured after 3
and 10 days of co-culture in direct contact or in transwell inserts.
Transwell co-culture induced an increase, even though less
pronounced, in secreted IL-8/CXCL8 and TNFα (Supplementary
Figure S3), suggesting that soluble crosstalk is also implicated in
this heterotypic cell interaction.
On the whole, these data indicated that HFF may increase
the survival of C91/PL cells in vitro and may contribute to
the induction of morphological and secretory changes similar
to those of C91/III cells. Most importantly, co-cultured C91/PL
cells were much more tumorigenic compared to the parental
cells when injected into baby NSG mice. On the other hand, the
remarkably overlapping viral expression patterns of C91/PL cells,
with or without HFF, argue against a role of viral genes in the
in vivo more aggressive behavior of co-cultured C91/PL cells and,
likely, of C91/III cells.
DISCUSSION
To recapitulate ATLL pathogenesis in vivo, transgenic and
humanized mouse models have been developed. Tax-transgenic
mice mainly developed arthropathy and other inflammatory
disorders (Iwakura et al., 1991; Yamamoto et al., 1993; Saggioro
et al., 1997) or solid tumor (Hinrichs et al., 1987; Nerenberg et al.,
1987) and leukemia (Grossman et al., 1995; Hasegawa et al., 2006;
Ohsugi, 2013), depending on the promoter used. HBZ-transgenic
mice develop not only T-cell lymphoma but also systemic chronic
inflammation after a long latency period and with low/variable
incidence (Satou et al., 2011). Thus, transgenic mice are useful
tools to investigate the activities of the Tax and HBZ proteins
but are limited in that the resulting phenotypes are dependent
on a given promoter and the functions of other viral products are
missing.
Further ATLL models exploiting the humanized mice
were recently developed, based on immunodeficient animals
transplanted with human hematopoietic stem cells from cord
blood or fetal liver, thus able to reconstitute a human
immune system permissive to HTLV-1 infection. Villaudy et al.
(2011) generated humanized mice by intrahepatic engraftment
of human cord blood CD34+ cells into Rag2−/−γc−/−
mice. During thymocyte maturation, these mice were infected
with intraperitoneal injection of irradiated MT-2 cells as
virus donors. Some of the animals, after a long latency,
showed pathological signs resembling the lymphoma variant
of ATLL. A different clinical presentation was achieved
in HTLV-1-infected humanized NOG mice (Tezuka et al.,
2014), showing ATLL-like leukemogenesis, characterized by
leukocytosis, hepatosplenomegaly, high plasmatic levels of
cytokines and sporadic appearance of flower cells in peripheral
blood. The humanized mouse model, although promising for
investigating the natural history of HTLV-1 infection and
the host-specific immune response, critical steps for eventual
development of ATLL, is however not easily achievable because
of the rather complex procedures including the ethics committee
evaluation for the use of human primary hematopoietic stem cells
and fetal tissues.
Engraftment of in vitro HTLV-1-infected and immortalized T
cells gave variable results in SCID mice, depending on which cell
line was tested (Feuer et al., 1993; Imada et al., 1995), and was
shown to be facilitated by abrogation of the host NK function
obtained through irradiation or treatment with an anti-asialo
GM1 antibody (Ishihara et al., 1992; Feuer et al., 1995).
Subsequent experiments on xenotransplantation of
in vitro HTLV-1-transformed T cell lines or peripheral blood
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FIGURE 4 | Soluble factors differentially released by C91/III cells. (A) Data are reported as ratio between the mean of the values, expressed in pg/mL/106 cells,
measured in the supernatants of C91/III cells and in the supernatants of C91/PL cells; standard deviations of the ratio are calculated according to the theory of error
propagation (Calabro et al., 2009). Only significantly different soluble factors are shown, and statistical significance is referred to the comparison of the concentration
values between the two cell lines, calculated by two-tailed Student’s t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (B) The figure schematically shows that some of
the soluble factors increased in the lymphomagenic cells belong to the HFF secretory profile, suggesting that C91/III cells acquired an autocrine stimulatory loop,
becoming independent from HFF support.
mononuclear cells from HTLV-1-infected asymptomatic carriers
in mice with various degrees of immunodeficiency confirmed
that lack of innate immunity is crucial for a favorable neoplastic
infiltration and/or outgrowth (Liu et al., 2002; Takajo et al., 2007).
This finding is consistent with the beneficial effect exerted by
alloreactive donor NK cells, generated following hematopoietic
stem cell transplantation, on the clinical outcome of leukemia
patients (Gismondi et al., 2015).
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FIGURE 5 | Analysis of the in vitro crosstalk of C91/PL cells and HFF. (A) Co-culture with HFF reduced apoptosis in C91/PL cells. Apoptosis was analyzed in
C91/PL cultured in standard conditions and in C91/PL cells co-cultured with HFF cells at 24, 48, and 72 h. Data are reported as ratio between the mean of the
percentage of Annexin V–positive cells in two different co-cultures and the standard deviations (SD) of the ratio are calculated among four different experimental
groups. Data are presented as mean ± SD. SD of the ratio was calculated according to the theory of error propagation. Statistical significance was determined by
two-tailed Student’s t-test. ∗p < 0.05, ∗∗p < 0.01. (B) Flow cytometry analysis of Annexin V/Propidium Iodide (PI) stained C91/PL cells cultured in standard
conditions (Upper) and in co-culture with HFF (Lower) at three different time points. A representative experiment is shown and the percentage of cells in each
quadrant of the flow plots is provided. (C) Measurement of the in vitro proliferation of C91/PL cells cultured in the absence (Left) or presence (Right) of HFF. Cells
were labeled with carboxyfluorescein succinimidyl ester (CFSE) and analyzed with XL Epic cytofluorimeter after 0 h (red), 24 h (green), 48 h (blue), and 72 h (violet).
The shaded histogram shows the unlabeled cells. The plots show that co-culture with HFF does not affect the proliferation rate of C91/PL cells. Histograms
represent the data obtained in two independent experiments. (D) Phase contrast images of C91/PL cells after co-culture with HFF. Eight-week-co-culture with HFF
induced an increase in giant cells, thus resembling the C91/III cell line. Original magnification 100×. (E) Kaplan–Meier survival curves for 5-day-old NSG mice i.p.
injected with 4 × 106 C91/PL cells (seven mice) and with 4 × 106 co-cultured C91/PL cells (nine mice). A statistically significant reduction (log-rank test; p = 0.0005)
in the overall survival of mice injected with co-cultured cells was observed. (F) Analysis of HTLV-1 transcripts. Quantitative analyses of viral transcripts showed no
significant variation in any of the HTLV-1 mRNAs in co-cultured C91/PL cells compared to the C91/PL cell line, suggesting that the increased survival and in vivo
lymphoma induction acquired by co-cultured cells were not likely due to virus-encoded factors. Data are reported as described in Figure 3B.
Therefore, to focus on the influence of host microenvironment
other than immune cell components, BALB/c Rag2−/−γc−/−
and BRG (“excluded flora”) mice, characterized by
immunological dysfunction of T, B, and NK cells, were
employed in the present study. By injecting intraperitoneally
newborn mice with C91/PL cells together with HFF a significant
triggering of lymphoma development was observed in two sets of
experiments (Table 1 and Figure 2A). The different percentage of
mice developing lymphoma in the two series of experiments may
likely be explained by mouse intra-strain genetic background
variation (Eisener-Dorman et al., 2009) and/or different gut
microbiota (Yamamoto and Schiestl, 2014; Rosshart et al.,
2017). Unfortunately, experiments could not be continued in
the Rag2−/−γc−/− mice first employed in our experiments, as
these animals are no longer available. C91/PL-derived cell lines
were further established, which consistently induced neoplastic
infiltration when injected alone in newborn and young adult
Rag2−/−γc−/− and NSG mice (Table 2 and Figure 2B). This
indicated that a stable and highly tumorigenic capacity was
acquired by C91/PL cells following co-transplantation with
HFF and subsequent in vitro/in vivo passages. Immunodeficient
mice xenotransplanted with C91/I, C91/II, and C91/III cell lines
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exhibited lymphomatous masses diffused to lungs, abdominal
and pelvic organs, reminiscent of the lymphoma variant of ATLL
(Figure 1). Their engraftment efficiency was more reproducible
and shorter in latency than that exhibited by the parental C91/PL
cells. Interestingly, the frequent lymphomatous involvement of
lungs in mice injected with C91/II and C91/III cells indicates an
increased lung tropism, a peculiar feature of ATLL cells. In fact,
pulmonary chronic inflammatory lesions were described in about
30% of HTLV-1 carriers and lung lymphomatous infiltration was
observed in 45% of ATLL patients (Yoshioka et al., 1985; Okada
et al., 2006).
The role of stromal microenvironment, and particularly of
fibroblasts, its major cellular component, on tumor induction
has been extensively documented in epithelial cancers, leading to
the notion that fibroblasts exhibit a bimodal effect (Bhowmick
et al., 2004; Kalluri and Zeisberg, 2006). In the initial phase
of tumorigenesis, they constrain the oncogenic conversion by
remodeling the stromal architecture, while in later stages they
promote tumor progression and invasiveness, engaging an
active crosstalk with the cancerous cells (Marsh et al., 2013;
Heneberg, 2016). Complex crosstalk between bone marrow
microenvironment and leukemia cells has also been reported,
and therapeutic interventions targeting leukemia niches have
been proposed (Jin et al., 2008; Zhang et al., 2012). Similarly,
lymphoma cells may interact with stromal components to acquire
a more aggressive and invasive behavior. In the setting of
ATLL, co-culture of clinical samples of ATLL cells, in vitro
HTLV-1-transformed and ATLL-derived cell lines with murine
bone marrow stromal cells supported the growth of primary
ATLL cells as well as established cell lines (Nagai et al., 2008).
The proliferative enhancement was paralleled by downregulation
of Tax, while the expression level of HBZ gene remained
unchanged (Nagai et al., 2008). Kinpara et al. (2009) also
found that co-culture of ATLL-derived or HTLV-1-transformed
T cells with human epithelial-like cells (HEK293T cells) or
with murine NIH3T3 fibroblasts did suppress viral p19 and gag
mRNA, and this effect, albeit reversible, was mediated by IFN-
α and IFN-β. ATLL cell lines and primary ATLL cells, after
short-term co-culture with epithelial-like cells were found to
be protected from apoptosis, became quiescent and acquired a
cancer stem cell-like phenotype (Miyatake et al., 2013, 2015). All
these findings highlight the relevant impact of microenvironment
in ATLL pathogenesis, indicating that stromal signaling may
contribute to the establishment of viral latency as well as
may induce in vitro a more aggressive neoplastic phenotype.
In the present study we show the role of human primary
fibroblasts in T-cell lymphomagenesis using an in vivo preclinical
setting.
Preliminary characterization of the lymphomagenic C91/III
cell line, derived from the parental C91/PL cells, did not show
relevant phenotypic changes (Table 3), but the analysis of
its secretory repertoire indicated that mechanisms involved in
epithelial cancers may also apply to ATLL. Indeed, a relevant
role in lymphomagenesis is played by cytokines and chemokines
which provide a milieu favorable to tumor growth and a
signaling path for cell migration and tissue invasion (Hsu et al.,
1993). The disseminated nature of the neoplasia developed in
C91/III-injected mice was paralleled by a substantial alteration
in the secretory profile of these cells, mainly characterized
by the significant increase of several soluble factors, most of
which equipped with a direct (IL-1α, IL-6, TNFα) or indirect
(mainly chemokines) pro-inflammatory activity (Figure 4). The
major fold increment was found in IL-8/CXCL8, an important
mediator for tissue infiltration (Balkwill and Mantovani, 2001).
Remarkably, some of the factors increased in C91/III cells also
belonged to the secretory profile of ATLL cells (Yamada et al.,
1996) as well as of HFF, and are known to facilitate tumor
progression in vivo (Davalos et al., 2010). These data suggest that
C91/III cells may autonomously induce a pro-inflammatory-like
status that, through autocrine and paracrine loops, is able
to promote tumorigenesis and organ infiltration. Interestingly,
the in vitro crosstalk of C91/PL cells with HFF led to
the acquisition of a pro-inflammatory secretory phenotype
similar to that observed in the tumorigenic C91/III cells
(Supplementary Figure S2). HFF-co-cultured C91/PL cells not
only changed their turn over, acquiring resistance to induced
apoptosis (Figures 5A,B) but, most importantly, acquired an
enhanced lymphomagenic capability upon xenotransplantation
(Figure 5E).
Transwell experiments also demonstrated a moderate increase
in IL-8/CXCL8 and TNFα secretion, thus suggesting that, in
addition to cell-to-cell contact, soluble factors play a role in
the heterotypic cell interaction (Supplementary Figure S3).
However, it should be mentioned that in vivo preliminary
experiments by co-injection of conditioned medium from HFF
with C91/PL cells failed to increase cell tumorigenesis (data
not shown). Additional studies are needed to further confirm
that HFF-secreted factors are not sufficient per se to modify the
in vivo behavior of C91/PL cells. The overall increase in the
expression of all viral accessory mRNAs observed in C91/III
cells (Figure 3B) might suggest the acquisition of defective
proviruses during the process of clonal evolution of these cells,
and denotes another feature reminiscent of ATLL cells in vivo
(Ohshima et al., 1991). However, HFF-co-cultured C91/PL cells
showed no significant differences in the viral transcriptional
profile (Figure 5F), suggesting that the increased tumorigenicity
of co-cultured cells, and likely of C91/III cells, is not driven by
viral factors.
Evolutionary models of cancer development imply the
existence of silent precursor cells from which, through a
stepwise process of accumulation of somatic mutations,
aggressive malignancies eventually rise (Greaves, 2015). Actually,
persistence of the pre-leukemic precursors, carrying a founder
mutation, albeit not malignant per se, has recently been
demonstrated in acute leukemia (Shlush et al., 2014). In the
ATLL setting, it may be envisaged that the insertion of the
HTLV-1 DNA provirus in the genome of T cells constitutes
the “founder” mutation conferring them the properties of
persistent, pre-malignant ancestors, which, upon additional
favorable forces, may ultimately reach full oncogenic capacity.
A well-known similar condition is represented by the long life
persistence of B cells immortalized by the Epstein-Barr virus
from which lymphomas may develop in immunosuppressed
subjects.
Frontiers in Microbiology | www.frontiersin.org 12 June 2018 | Volume 9 | Article 1215
fmicb-09-01215 June 11, 2018 Time: 17:14 # 13
Vicario et al. A Preclinical Model for the ATLL Lymphoma Variant
CONCLUSION
The finding that fibroblasts possessing an activated-
like, pro-inflammatory secretory phenotype enhance the
tumorigenesis of C91/PL cells throws light on the triggering
activity of the host microenvironment on HTLV-1-linked
lymphomagenesis. More work is needed to clarify the basis
of this triggering effect as well as to reveal whether genetic
and epigenetic changes, produced within the HTLV-1-
immortalized T cells, share the responsibility for full-blown
malignancy.
Furthermore, our results show that the C91/III cell line,
originating from a long-term in vitro HTLV-1-immortalized T
cell line, is endowed with a highly reproducible lymphomagenic
capacity in NSG mice that may be exploited as a simple
murine preclinical model to investigate in vivo the efficacy
of therapeutic interventions against the lymphoma variant of
ATLL.
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FIGURE S1 | Representative photomicrographs of immunoreactions for CD25
showing lymphomatous infiltration in the lung parenchyma (A) and a nearby
pulmonary bronchiole (B) observed in a C91/III cell-injected mouse. Original
magnification 400×.
FIGURE S2 | Soluble factors released by C91/PL cells after co-culture with HFF.
Cytokines, chemokines and growth factors secreted in culture supernatants by
C91/PL cells removed after 2 months from the co-culture with HFF and
maintained as long as 6 weeks in culture. Values are normalized to those of
C91/PL cells. Data are reported as ratio between the mean of the values,
expressed in pg/mL/106 cells, measured in co-cultured C91/PL cells and the
mean of the values measured in the supernatants of C91/PL cells, and the
standard deviations of the ratio are calculated according to the theory of error
propagation (Calabro et al., 2009). Only significantly different soluble factors are
shown, and statistical significance was determined by two-tailed Student’s t-test.
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
FIGURE S3 | IL-8/CXCL8 and TNFα released in culture supernatants after
short-term co-culture of C91/PL cells with HFF. A significant increase in the
secretion of IL-8/CXCL8 (A) and TNFα (B) was observed after 3 days of co-culture
of C91/PL cells, either in direct contact or placed in transwell inserts, with HFF;
IL-8/CXCL8 increment persisted after 10 days of co-culture. Control wells with
C91/PL cells or HFF were set up and analyzed in parallel. As previously observed
(Supplementary Table S2), HFF did not contribute to TNFα increase. The
increase in IL-8/CXCL8 and TNFα in transwell co-cultures, albeit lower than that
measured in direct co-cultures, indicated that the heterotypic crosstalk is also
mediated by soluble factors. Data are expressed in pg/mL/106 cells. Statistical
significance was calculated by two-tailed Student’s t-test. ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
TABLE S1 | Short Tandem Repeat (STR) profiles of cell lines.
TABLE S2 | Soluble factors released by C91/PL and C91/III cells and human
foreskin fibroblasts (HFF).
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